Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by sah1on May 18, 2017 4:11pm
185 Views
Post# 26261433

RE:RE:RE:Gunner4CornHole + CDJerkoff1234: Shorters

RE:RE:RE:Gunner4CornHole + CDJerkoff1234: ShortersGunner, my original post said September which I believe still has 30 days.

However, my basic point is that the decision on priority review is not that far off and I believe it could be a catalyst. Also, PLI has applied for pediatric designation and hopefully that decision will be made at the same time as Priority Review. One will soon find out:-)

Previous post
i believe that a key trigger point will be FDA's decision on priority review. This will signal to the market that Pg will be approved in the very near term (no later than September) and that revenues from this therapeutic will start to grow. The decision on priority review is due between now and June 5th. If positive, I believe the smart money will start to move into the stock to get in early on what is going to be a blockbuster franchise. IMHO
Bullboard Posts